대한암한의학회지 (Journal of Korean Traditional Oncology)

  • 제24권1호
  • /
  • Pages.19-28
  • /
  • 2019
  • /
  • 1975-244X(pISSN)
  • /
  • 2765-4850(eISSN)
대한암한의학회 (Korean Association of Traditional Oncology)
권호 표지
DOI QR코드

DOI QR Code

전이성 유방암 환자의 통합 암 치료에 대한 증례보고

A Case Report of Metastatic Breast Cancer Patient Treated with Integrative Cancer Treatment

  • 하수정 (대전대학교 둔산한방병원 동서암센터) ;
  • 이성철 (대전대학교 둔산한방병원 동서암센터) ;
  • 박소정 (대전대학교 둔산한방병원 동서암센터) ;
  • 전형준 (대전대학교 둔산한방병원 동서암센터) ;
  • 이연월 (대전대학교 둔산한방병원 동서암센터) ;
  • 조종관 (대전대학교 둔산한방병원 동서암센터) ;
  • 유화승 (대전대학교 둔산한방병원 동서암센터)
  • Ha, Su-jeong (East West Cancer Center, Dunsan Korean Medicine Hospital of Daejeon University) ;
  • Lee, Sung-cheol (East West Cancer Center, Dunsan Korean Medicine Hospital of Daejeon University) ;
  • Park, So-jung (East West Cancer Center, Dunsan Korean Medicine Hospital of Daejeon University) ;
  • Jeon, Hyung-joon (East West Cancer Center, Dunsan Korean Medicine Hospital of Daejeon University) ;
  • Lee, Yeon-Weol (East West Cancer Center, Dunsan Korean Medicine Hospital of Daejeon University) ;
  • Cho, Chong-kwan (East West Cancer Center, Dunsan Korean Medicine Hospital of Daejeon University) ;
  • Yoo, Hwa-seung (East West Cancer Center, Dunsan Korean Medicine Hospital of Daejeon University)
  • 투고 : 2019.06.05
  • 심사 : 2019.06.23
  • 발행 : 2019.06.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objective : The purpose of this study is to report and observe effects of Integrative Cancer Treatment (ICT) on metastatic breast cancer patient. Method : A left breast cancer patient diagnosed with recurrence on liver and bones April 2018. The patient had received paclitaxel chemotherapy for two months and discontinued it because of tumor progression and side effects. The patient has been treated with ICT since March 2018 and has been taking capecitabine since October 2018. The clinical outcomes were measured by computed tomography, laboratory findings including tumor markers (CEA, CA15-3). The clinical outcomes were measured by computed tomography, laboratory findings including tumor markers (CEA, CA15-3), liver function test (AST, ALT), Eastern Cooperative Oncology Group performance status (ECOG PS), and numeric rating scales (NRS). Results : After the ICT, tumor size was partially decreased accompanying by reducing the levels of tumor markers. Major clinical symptoms induced by paclitaxel chemotherapy were improved. There were no severe adverse events induced by ICT based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. Conclusion : This case suggests that ICT may have synergistic effect for the treatment of metastatic breast cancer patient in conjunction with capecitabine.

키워드

HJJJCF_2019_v24n1_19_f0001.png 이미지

Figure 1. Comparison of abdomen computed tomography

HJJJCF_2019_v24n1_19_f0002.png 이미지

Figure 2. Bone scan

HJJJCF_2019_v24n1_19_f0003.png 이미지

Figure 3. Changes of numeric rating scale on clinical symptom

Table 1. Prescription of Herbal medication

HJJJCF_2019_v24n1_19_t0001.png 이미지

Table 2. Tumor marker Follow-up

HJJJCF_2019_v24n1_19_t0002.png 이미지

Table 3. Liver Function Test Follow-up

HJJJCF_2019_v24n1_19_t0003.png 이미지

참고문헌

  1. Hortobagyi G, Connolly JL, D'Orsi CJ, Edge SB, Mittendorf EA, Rugo HS, Solin LJ, Weaver DL, Winchester DJ, Giuliano A. AJCC cancer staging manual, 8th edn. Springer, New York, 587-628, 2017
  2. Lee SB, Sohn G, Kim J, Chung IY, Lee JW, Kim HJ, Ko BS, Son BH, Ahn SH. A retrospective prognostic evaluation analysis using the 8th edition of the American Joint Committee on Cancer staging system for breast cancer. Breast Cancer Res Treat 169(2):257-266, 2018 https://doi.org/10.1007/s10549-018-4682-5
  3. Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Biganzoli L, Blackwell KL, Cardoso MJ, Cufer T, El Saghir N, Fallowfield L, Fenech D, Francis P, Gelmon K, Giordano SH, Gligorov J, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Krop I, Kyriakides S, Lin UN, Mayer M, Merjaver SD, Nordström EB, Pagani O, Partridge A, Penault-Llorca F, Piccart MJ, Rugo H, Sledge G, Thomssen C, Van't Veer L, Vorobiof D. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer. Ann Oncol 25(10):1871-1888, 2014 https://doi.org/10.1093/annonc/mdu385
  4. Yin WJ, Pei GS, Liu G, Huang L, Gao SG, and Feng XS. Efficacy and safety of capecitabine-based first-line chemotherapy in advanced or metastatic breast cancer: a meta-analysis of randomised controlled trials. Oncotarget 6(36):39365-39372, 2015 https://doi.org/10.18632/oncotarget.5460
  5. Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, Kuroi K, Im SA, Park BW, Kim SB, Yanagita Y, Ohno S, Takao S, Aogi K, Iwata H, Jeong J, Kim A, Park KH, Sasano H, Ohashi Y, Toi M. Adjubant capecitabine for breast cancer after preoperative chemotherapy. N Enql J Med 376(22):2147-2159, 2017 https://doi.org/10.1056/NEJMoa1612645
  6. Jin YJ, Shin KS, Ha JY. Case of remission of progressive breast cancer treated by capecitabine with Integrative Medicine Therapy. J of Kor Traditional Oncol 19(1):43-51, 2014 https://doi.org/10.15432/JKTO.2014.19.1.43
  7. Li YQ, Zeng BH, Du ZQ. Capecitabine combined with compound Chinese medicine treating advanced and recurrent colorectal cancer. Modern hosp 10(8), 2011
  8. Zhen LV. Therapeutic effects of capecitabine and chinese medicine for advanced gastrointestinal cancer. J of nanjing TCM univercity 26(6), 2010
  9. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R. New response evaluation criteria in solid tumors. Revised RECIST guideline(version 1.1). Eur J Cancer 45: 228-247, 2009 https://doi.org/10.1016/j.ejca.2008.10.026
  10. National Cancer Institute. Common Terminology Criteria for Adverse Events(CTCAE) v.5.0, 2017. Available from https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_5.0/
  11. Gwak MD, Suh SY. The assessment tools in palliative medicine. Kor J Hosp Palliat Care 12:177-193, 2009 https://doi.org/10.14475/kjhpc.2009.12.4.177
  12. Lee DE, Lee SY, Kim JS, Cho CK, Yoo HS, Choi SJ. Antitumor effect of Hang-Am-Dan (HAD) and its ingredients on Calu6 and MCF-7 human cancer cell lines. J of Kor Oriental Med 30(5):50-60, 2009
  13. Choi BL, Lee YY, Yoo HS, Seo SH, Choi WJ, Cho JH, Lee YW, Son CK, Cho CK, Song KC. The Clinical study in 60 cases for breast cancer patients on the effects by Hangamdan. J of Int Kor Med 22(4):669-674, 2001
  14. Choi W, Jung H, Kim K, Lee S, Yoon S, Park J, Kim S, Cheon S, Eo W, Lee S. Rhus verniciflua stokes against advanced cancer: a perspective from the Korean Integrative Cancer Center. Biomed Res Int 2012:1-7, 2011
  15. 김덕호, 김정제, 김병운, 우홍정. 柴胡淸 肝湯이 $CCl_4$ 中毒白鼠의 肝損傷에 미치는 影響에 關하여. 경희한의대논문집. 3(1):205-212, 1980
  16. Garaci E, Pica F, Rasi G, Favalli C. Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application. Int J Immunopharmacol 22:1067-1076, 2000 https://doi.org/10.1016/S0192-0561(00)00075-8
  17. Zee J. Heating the patient: a promising approach. Ann Oncol 13(8):1173-1184, 2002 https://doi.org/10.1093/annonc/mdf280
  18. "Capecitabine Teva : EPAR - Product Information" (PDF). European Medicines Agency. Teva Pharma B.V. 7-9, 2014
  19. パクリタキセル注射液使用ガイド:ブリストル, マイヤーズ株式會社.
  20. Y Shindo. Japanese traditional KAMPO medicine reduce toxicities with colorectal cancer cemotherapy. GI-ESMO 375, 2011
  21. Song SY, Bae K, Shin KH, Yoo HS. A case series of snake venom pharmacopuncture for chemotherapy-induced peripheral neuropathy: a retrospective observational study. J of Pharmacopuncture 20(4):280-286, 2017 https://doi.org/10.3831/KPI.2017.20.034
  22. Blum JL, Barrios CH, Feldman N, Verma S, McKenna EF, Lee LF, Scotto N, Gralow J. Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer. Breast Cancer Res Treat 136(3):777-788, 2012 https://doi.org/10.1007/s10549-012-2288-x